Table 1.
Demographic and clinical characteristics of the study population
| One-year post-diagnosis | Total (n=206) | Survivor (n=174) | Death (n=32) | p-value |
|---|---|---|---|---|
| Demographic variable | ||||
| Age at diagnosis (yr) | ||||
| 20-44 | 71 (34.5) | 60 (34.5) | 11 (34.4) | 0.321 |
| 45-54 | 78 (37.9) | 69 (39.7) | 9 (28.1) | |
| ≥ 55 | 57 (27.7) | 45 (25.9) | 12 (37.5) | |
| Mean±SD | 47.3±9.1 | 47.0±9.1 | 48.7 (9.7) | 0.353a) |
| Education level at diagnosis | ||||
| ≤ High school | 151 (73.7) | 126 (72.4) | 25 (80.7) | 0.338 |
| ≥ University | 54 (26.3) | 48 (27.6) | 6 (19.3) | |
| Having religion | ||||
| No | 52 (25.5) | 48 (27.9) | 4 (12.5) | 0.066 |
| Yes | 152 (74.5) | 124 (72.1) | 28 (87.5) | |
| Job status | ||||
| No | 117 (62.6) | 99 (63.5) | 18 (58.1) | 0.571 |
| Yes | 70 (37.4) | 57 (36.5) | 13 (41.9) | |
| Monthly income (USD) | ||||
| < 2,000 | 81 (43.1) | 68 (42.0) | 13 (50.0) | 0.443 |
| ≥ 2,000 | 107 (56.9) | 94 (58.0) | 13 (50.0) | |
| Marital status | ||||
| Married | 166 (81.0) | 139 (80.4) | 27 (84.4) | 0.594 |
| Others | 39 (19.0) | 34 (19.7) | 5 (15.6) | |
| Drinking | ||||
| Yes | 16 (8.3) | 147 (90.7) | 29 (96.7) | 0.281 |
| No | 176 (91.7) | 15 (9.3) | 1 (3.3) | |
| Smoking | ||||
| Yes | 3 (1.6) | 161 (98.8) | 28 (96.6) | 0.374 |
| No | 189 (98.4) | 2 (1.2) | 1 (3.5) | |
| Clinical characteristic | ||||
| Comorbidity status | ||||
| No | 130 (69.2) | 116 (73.0) | 14 (48.3) | 0.008 |
| Yes | 58 (30.9) | 43 (27.0) | 15 (51.7) | |
| Radiotherapy | ||||
| No | 43 (21.0) | 36 (20.8) | 7 (21.9) | 0.892 |
| Yes | 162 (79.0) | 137 (79.2) | 25 (78.1) | |
| Duration of radiotherapy (day) | ||||
| Mean±SD | 46.7±21.5 | 45.5±11.2 | 53.8±51.0 | 0.093a) |
| Chemotherapyb) | ||||
| No | 28 (13.7) | 28 (16.2) | 0 | NA |
| Yes | 177 (86.3) | 145 (83.8) | 32 (100) | |
| Duration of chemotherapy (day) | ||||
| Mean±SD | 116.0±42.8 | 113.8±36.3 | 125.6±64.6 | 0.161a) |
| Hormone therapy | ||||
| No | 39 (18.9) | 35 (20.1) | 4 (12.5) | 0.312 |
| Yes | 167 (81.1) | 139 (79.9) | 28 (87.5) | |
| Stage | ||||
| I-IIA | 131 (63.6) | 121 (69.5) | 10 (31.3) | < 0.001 |
| IIB-IVc) | 75 (36.4) | 53 (30.5) | 22 (68.8) | |
| Breast cancer tumor subtypesb) | ||||
| ER/PR+, HER2+ | 11 (5.4) | 10 (5.8) | 1 (3.2) | NA |
| ER/PR+, HER2– | 156 (76.1) | 129 (74.1) | 27 (87.1) | |
| ER/PR–, HER2+ | 13 (6.3) | 11 (6.3) | 2 (6.5) | |
| ER/PR–, HER2– | 25 (12.2) | 24 (13.8) | 1 (3.2) |
Values are presented as number (%) unless otherwise indicated. SD, standard deviation; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
a)
p-value was obtained from the Kruskal-Wallis test,
b)
NA, not available (due to small number of participant),
c)
Five participants with stage IV.
Other p-values were obtained by Fisher's exact test.